Guangzhou Trauer Biotechnology Co., Ltd (Trauer Bio) has released its 2023 annual report. During the reporting period, the company achieved a revenue of 306 million yuan, an increase of 64.0889 million yuan, or 26.48%, compared to the same period last year. Among them, the sales revenue of Trauer brand medical devices increased by 17.7335 million yuan compared to the same period last year; sales of Trauer brand skincare products steadily increased after their launch, achieving sales revenue of 80.015 million yuan in 2023, an increase of 53.7741 million yuan compared to the previous year.
Due to market competition, sales revenue of Trauemy brand skincare products decreased by 7.7526 million yuan compared to the same period last year. Net profit increased by 11.7511 million yuan compared to the same period last year, a year-on-year increase of 33.43%.
Trauer Bio stated that during the reporting period, the company mainly focused on research and development of active collagen products and technologies. The research and development projects of the company and its subsidiaries mainly include the development of new medical device products, the development of functional skincare products, and the optimization of product processes. During the reporting period, the company and its subsidiaries conducted a total of 28 research and development projects, completing 11 projects and having 17 projects in progress.
Founded in August 2002, Guangzhou Trauer Biotechnology Co., Ltd., is an advanced technology company engaged in the research, development, manufacturing, and distribution of biomedical active collagen materials. It specializes in bio-active collagen materials, medical devices, and biocosmetic products, with expertise in key technological aspects of these fields.
In the field of bio cosmetics, Trauer Bio is rooted in the large-scale sterile extraction and preparation technology of bio-medical-grade active collagen. It focuses on developing efficient, simple, and safe formula products with daily maintenance and skin barrier repair functions, aiming to create multidimensional and multi-series biocosmetic solutions.
Looking ahead, Trauer Bio states that it will drive its development with technological innovation as the primary driving force. It will further leverage its comprehensive competitive advantages in research and development, production, and quality management, accelerate the launch of new products, and form a sustainable and tiered product portfolio. This portfolio will provide patients with more technologically advanced and competitively positioned products in skin disease treatment, wound care, oral repair, sports medicine injury repair, and other fields.
